DMAC - DiaMedica Therapeutics up ~5% reports directors and execs buying stock
2023-06-27 02:52:23 ET
- Clinical stage biopharmaceutical company, DiaMedica Therapeutics ( NASDAQ: DMAC ) rose 4.5% to $4.40 on Monday late hours. The company filed Form 4 that shows executives and directors buying company stock.
- Director Randall Michael Giuffre bought 65,000 shares at $3.91 on June 23, 2023.
- President and CEO Dietrich John Pauls bought 12,787 shares at $3.91 on the same date.
- Director Charles Pauling Semba bought 12,787 at $3.91.
- CFO and Secretary Scott Kellen bought 10,000 shares at $3.91.
- Chief Business Officer David J. Wambeke bought 38,364 shares at $3.91.
- Director, Richard D. Pilnik bought 38,363 shares at $3.91.
- The company's stock price has surged about 55% during the last month, and sell-side analysts give the stock a Strong Buy Rating with a target price of $8.33.
For further details see:
DiaMedica Therapeutics up ~5%, reports directors and execs buying stock